CITADELLKLINIKEN ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  17.3% 16.6% 10.3% 19.3% 14.9%  
Credit score (0-100)  10 11 24 6 13  
Credit rating  BB BB BB B BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Gross profit  -2.9 -2.4 94.6 1,410 421  
EBITDA  -2.9 -2.4 94.6 1,410 421  
EBIT  -2.9 -2.4 94.6 1,410 421  
Pre-tax profit (PTP)  -3.3 -2.8 71.3 1,333.1 355.2  
Net earnings  -3.3 -2.8 60.1 1,037.0 277.1  
Pre-tax profit without non-rec. items  -3.3 -2.8 71.3 1,333 355  

 
See the entire income statement

Balance sheet (kDKK) 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  61.9 59.1 119 1,156 1,433  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  61.9 59.1 1,199 2,850 2,472  

Net Debt  -61.9 -59.1 -619 -2,442 -174  
 
See the entire balance sheet

Volume 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -2.9 -2.4 94.6 1,410 421  
Gross profit growth  0.0% 16.7% 0.0% 1,389.5% -70.1%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  62 59 1,199 2,850 2,472  
Balance sheet change%  -5.1% -4.6% 1,929.1% 137.6% -13.3%  
Added value  -2.9 -2.4 94.6 1,409.6 421.3  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -3.0 -4.0 1.0 2.0 3.0  

Profitability 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  100.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -4.6% -4.0% 15.1% 72.0% 20.5%  
ROI %  -4.6% -4.0% 106.6% 228.5% 42.1%  
ROE %  -5.2% -4.7% 67.4% 162.6% 21.4%  

Solidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Equity ratio %  100.0% 100.0% 9.9% 40.6% 58.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  2,135.5% 2,444.9% -653.7% -173.2% -41.3%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Quick Ratio  0.0 0.0 1.1 1.7 2.4  
Current Ratio  0.0 0.0 1.1 1.7 2.4  
Cash and cash equivalent  61.9 59.1 618.6 2,441.8 173.9  

Capital use efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  61.9 59.1 119.2 1,156.2 1,433.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2018
2018/12
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0